Brokerages Set $13.50 Target Price for Valeritas Holdings, Inc. (VLRX)

Shares of Valeritas Holdings, Inc. (NASDAQ:VLRX) have been given an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.

Brokers have set a 1 year consensus price target of $13.50 for the company, according to Zacks. Zacks has also given Valeritas an industry rank of 187 out of 265 based on the ratings given to its competitors.

Separately, ValuEngine raised shares of Valeritas from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st.

Shares of Valeritas (VLRX) traded up $0.08 during mid-day trading on Wednesday, reaching $2.98. 1,170 shares of the company’s stock traded hands, compared to its average volume of 9,453. The firm has a market cap of $21.09, a price-to-earnings ratio of -0.22 and a beta of 4.91. The company has a debt-to-equity ratio of -8.88, a quick ratio of 2.40 and a current ratio of 3.02. Valeritas has a 52 week low of $2.00 and a 52 week high of $25.54.

TRADEMARK VIOLATION NOTICE: This report was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at

About Valeritas

Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.

Get a free copy of the Zacks research report on Valeritas (VLRX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with's FREE daily email newsletter.

Leave a Reply